https://scholars.lib.ntu.edu.tw/handle/123456789/568396
標題: | Global patterns of hepatocellular carcinoma management from diagnosis to death: The BRIDGE Study | 作者: | Park J.-W. Chen M. Colombo M. Roberts L.R. Schwartz M. PEI-JER CHEN Kudo M. Johnson P. Wagner S. Orsini L.S. Sherman M. |
關鍵字: | Disease management; Epidemiology; Global trends; Liver cancer; Observational study; Risk factors; Treatment patterns | 公開日期: | 2015 | 出版社: | Blackwell Publishing Ltd | 卷: | 35 | 期: | 9 | 起(迄)頁: | 2155-2166 | 來源出版物: | Liver International | 摘要: | Background & Aims: Hepatocellular carcinoma (HCC) is the second most common cause of cancer deaths worldwide. The global HCC BRIDGE study was a multiregional, large-scale, longitudinal cohort study undertaken to improve understanding of real-life management of patients with HCC, from diagnosis to death. Methods: Data were collected retrospectively from January 2005 to September 2012 by chart reviews of eligible patients newly diagnosed with HCC at participating institutions. Results: Forty-two sites in 14 countries contributed final data for 18?031 patients. Asia accounted for 67% of patients, Europe for 20% and North America for 13%. As expected, the most common risk factor was hepatitis C virus in North America, Europe and Japan, and hepatitis B virus in China, South Korea and Taiwan. The most common Barcelona Clinic Liver Cancer stage at diagnosis was C in North America, Europe, China and South Korea, and A in Taiwan and Japan. Across all stages, first HCC treatment was most frequently transarterial chemoembolization in North America, Europe, China and South Korea, percutaneous ethanol injection or radiofrequency ablation in Japan and resection in Taiwan. Survival from first HCC treatment varied significantly by region, with median overall survival not reached for Taiwan and 60, 33, 31, 24 and 23?months for Japan, North America, South Korea, Europe and China respectively (P?0.0001). Conclusions: Initial results from the BRIDGE study confirm previously reported regional trends in patient demographic characteristics and HCC risk factors, document the heterogeneity of treatment approaches across regions/countries and underscore the need for earlier HCC diagnosis worldwide. ? 2015 John Wiley & Sons A/S. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984564079&doi=10.1111%2fliv.12818&partnerID=40&md5=71102113b31d32d4d2635a688ca2c3b9 https://scholars.lib.ntu.edu.tw/handle/123456789/568396 |
ISSN: | 1478-3223 | DOI: | 10.1111/liv.12818 | SDG/關鍵字: | sorafenib; alcohol; adult; aged; Article; cancer chemotherapy; cancer diagnosis; cancer mortality; cancer staging; chemoembolization; China; cohort analysis; controlled study; Europe; female; Hepatitis B virus; Hepatitis C virus; human; Japan; liver cell carcinoma; liver resection; longitudinal study; major clinical study; male; medical record review; North America; overall survival; radiofrequency ablation; risk factor; South Korea; Taiwan; artificial embolization; Asia; Carcinoma, Hepatocellular; catheter ablation; clinical trial; complication; disease management; epidemiology; hepatitis B; hepatitis C; Liver Neoplasms; middle aged; mortality; multicenter study; retrospective study; survival analysis; virology; Adult; Aged; Asia; Carcinoma, Hepatocellular; Catheter Ablation; Disease Management; Embolization, Therapeutic; Ethanol; Europe; Female; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Longitudinal Studies; Male; Middle Aged; North America; Retrospective Studies; Risk Factors; Survival Analysis |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。